Mfg Part Number
Ab00726-2.0
Vector Labs Ab00726-2.0 Anti-CCR4 [KW-0761 (Mogamulizumab)], Mouse IgG2a, kappa (200 μg)
Quick Overview
This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
$517.40
Order will ship within 1-3 business days
| Product Class: | Purified |
|---|---|
| Clone ID: | KW-0761 (Mogamulizumab) |
| Synonyms: | CD194; CKR-4; CCR-4; CCR4; K5-5 |
| Amount: | 200 μg |
| Application Codes Clone: | Deplete |
| Shipping Temperature: | Wet Ice |
| Buffer Composition: | PBS with 0.02% Proclin 300. |
| Original Format: | IgG1 |
| Storage Temperature: | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C. |
| Chimeric Use Statement: | This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
| Specificity Statement: | This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells. |
| Application Notes: | The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated. |
| Brand | Vector Labs |
|---|---|
| UNSPSC | 12161500 |